Huber loss

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Retrieved on: 
Wednesday, March 20, 2024
Oculoplastics, Patient, Private practice, Webcast, TED, Cohort, Standard of care, NEJM, MD, Graves' ophthalmopathy, Hyperglycemia, Safety, Huber loss, Orbital, Medical device

LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.

Key Points: 
  • There have been no reports of hyperglycemia or hearing impairment and no serious adverse events.
  • “It is very encouraging to see the results of subcutaneous administration of an anti-IGF-1R therapy.
  • The data shown suggest that there is a clinically meaningful response in patients as early as 3 weeks after a single subcutaneous dose of lonigutamab.
  • “It is important to note that this is preliminary data in a small group, however the positive results are highly promising.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Sudden Hearing Loss: AudioCure's Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS

Retrieved on: 
Monday, April 1, 2024
General Health, Health, Science, Pharmaceutical, Research, Speech, Radical, Regeneration, Hearing loss, Patient, PNAS, Noise-induced hearing loss, Hope, Death, Neuron, Huber loss, Safety, CSO, Multimedia, Pharmaceutical industry

A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models.

Key Points: 
  • A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models.
  • Sudden hearing loss is often treated with anti-inflammatory corticosteroids without regulatory approval or reliable evidence of effectiveness.
  • A single middle ear application of AC102 after noise trauma restores hearing to near pre-trauma levels after 14 days.
  • Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma, explains, "The HODOKORT study highlights the treatment gap for sudden hearing loss.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

Three PMR Attorneys Included on List of Nation’s Top Plaintiff Lawyers

Retrieved on: 
Wednesday, March 13, 2024
Legal, Professional Services, Professional, Thomson Reuters, The National Law Journal, Apple, Lawyer, PMR, LLP, Peer review, AirPods, Huber loss

Paranjpe Mahadass Ruemke LLP, or PMR Law, is pleased to announce that Lawdragon has honored three of the firm’s attorneys in its 500 Leading Plaintiff Consumer Lawyers guide for 2024.

Key Points: 
  • Paranjpe Mahadass Ruemke LLP, or PMR Law, is pleased to announce that Lawdragon has honored three of the firm’s attorneys in its 500 Leading Plaintiff Consumer Lawyers guide for 2024.
  • Both are consistently honored for plaintiffs work by The Best Lawyers in America and Texas Super Lawyers, published by Thomson Reuters.
  • Texas Lawyer magazine has ranked PMR Law among Houston’s best personal injury firms for two consecutive years in its “Best of” listing.
  • PMR Law’s priority is to provide personalized attention, professionalism and tireless representation.

Sudden Hearing Loss: Recent Clinical Trial HODOKORT Questions Benefits of Glucocorticoid Treatment

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Speech, Glucocorticoid, Hearing loss, Patient, NEJM, Human, Trial of the century, Huber loss, Clinical trial, Multimedia, Steroid, Pharmaceutical industry

High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss.

Key Points: 
  • High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss.
  • This clinical study, led by Prof. Stefan Plontke from the University Medicine Halle, evaluated the efficacy of different doses of glucocorticoids in over 300 sudden hearing loss patients and is published in NEJM Evidence .
  • However, there is no convincing mode-of-action for the treatment of sudden hearing loss with steroids, as our own research has shown," says Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma.
  • After 50 years of treating sudden hearing loss with glucocorticoids, a new and effective drug for this condition would represent a much-needed paradigm shift.

Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation

Retrieved on: 
Monday, March 11, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Genetics, Clinical Trials, Cochlear Limited, Cochlear, Patient, Cochlea, POC, Perilymph, Huber loss, Data, Hearing, Physician, Medical device

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.

Key Points: 
  • Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.
  • The study has been developed in collaboration with Cochlear Limited (Cochlear), the global leader in implantable hearing devices.
  • On February 1, 2024, Sensorion announced the completion of patient inclusion in the Phase 2a clinical trial of SENS-401 for the residual hearing preservation after cochlear implantation.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: "We are delighted to announce we met the primary endpoint for the Phase 2a clinical trial of SENS-401 for residual hearing preservation.

Chosgo K23: One of the Best Bluetooth Hearing Aids for Seniors

Retrieved on: 
Friday, March 29, 2024
Huber loss, DSP, Hearing aid, IPhone, Risk, Policy, Sale, Quality of life, TWS, Kool-Aid, Hearing loss, OTC, CIC, Music, Mobile, Multimedia, FDA, Hearing, Android, Deficit spending, Bluetooth

ALBANY, N.Y., March 29, 2024 /PRNewswire-PRWeb/ -- The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can favor the onset of cognitive deficits of various types. People affected by hearing loss, therefore with hearing problems, have a risk twice as high as others of developing dementia.

Key Points: 
  • Hearing aids for seniors are almost a necessity and when it comes time to choose, OTC hearing aids like the Chosgo K23 offer even more advantages.
  • However, an FDA policy last October allowing the sale of OTC hearing aids without a prescription has resulted in massive price drops and less oversight of the OTC hearing aids flooding the market.
  • As a result, we recommend one product that we think is one of the best OTC hearing aids .
  • Hearing aids for seniors are almost a necessity and when it comes time to choose, OTC hearing aids like the Chosgo K23 offer even more advantages.

Sony Group Exhibits at the World's Largest International Conference on Accessibility "CSUN Assistive Technology Conference 2024"

Retrieved on: 
Monday, March 18, 2024
Friends, PS5, Ear canal, Braille, Sony Interactive Entertainment, Hearing aid, System, Creativity, Disability, Visual impairment, Television, SAN, Purpose, PlayStation Store, PS4, FX3, PlayStation, Access, PlayStation Studios, IOS, Braille Institute of America, WS Audiology, Organization, Home, Sony, BRAVIA, Senior, Ear, App Store (iOS/iPadOS), OTC, Orientation, Lighthouse, FDA, SONY, Smartphone, Conference, Environment, Name, Light, Imaging, Motion, Home entertainment, Audiology, Google Play, Kool-Aid, Retina, Google TalkBack, Music, Huber loss, Multimedia, Hearing, Video game

SAN DIEGO, March 18, 2024 /PRNewswire/ -- Sony Group ("Sony") announced today that it will have an exhibit at the world's largest international conference on accessibility, the "CSUN Assistive Technology Conference 2024" March 18 to 22 in Anaheim, California.

Key Points: 
  • SAN DIEGO, March 18, 2024 /PRNewswire/ -- Sony Group ("Sony") announced today that it will have an exhibit at the world's largest international conference on accessibility, the "CSUN Assistive Technology Conference 2024" March 18 to 22 in Anaheim, California.
  • Developed in collaboration with the accessibility community, the Access controller features an expansive array of hardware and software customization options.
  • In addition to the above exhibits, Sony will hold Conference Sessions to showcase a selection of accessibility initiatives.
  • Shiro Kambe, Senior Executive Vice President, Sony Group Corporation, and Neal Manowitz, President and COO of Sony Electronics North America, will share video messages regarding accessibility at Sony.

HIMSS24: Linus Health Unveils Two New Evidence-Based, Digital Cognitive Screening Additions to its Comprehensive Brain Health Platform

Retrieved on: 
Monday, March 11, 2024
Research, Digital, Conference, Dementia, Confusion, Deficit spending, Alzheimer's disease, Patient, Linus, Triage, Standard of care, AI, MD, Ear, Hearing loss, MCI, Exhibition, Machine learning, Huber loss, Medicare, FDA, Hearing, Physician, Medical device

BOSTON, March 11, 2024 /PRNewswire/ -- Linus Health, a digital health company focused on enabling early detection of Alzheimer's and other dementias, announced today the expansion of its innovative, evidence-based suite of cognitive health assessments with the Hearing Screener and the Digital Trail Making Test Part B (dTMT). These essential additions to Linus Health's AI-enhanced digital cognitive assessment platform accelerate and simplify the early detection and management of mild cognitive impairment (MCI), a precursor to Alzheimer's Disease.

Key Points: 
  • These essential additions to Linus Health's AI-enhanced digital cognitive assessment platform accelerate and simplify the early detection and management of mild cognitive impairment (MCI), a precursor to Alzheimer's Disease.
  • Meanwhile, the Linus Health dTMT is rooted in an executive functioning assessment trusted for eight decades but now revolutionized through innovative AI, machine learning and digital health technologies.
  • "The Linus Health digital cognitive assessment platform continues to grow with practical tools to enable primary care physicians and specialists to easily adopt cognitive assessments as part of the standard of care.
  • Linus Health will demonstrate its new Hearing Screener and dTMT at the 2024 HIMSS Global Health Conference & Exhibition in Orlando, March 11-15.